Citations

Clear

1893 citation(s) found for "Wu, Kenneth".

Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma
Kizilbash, Sani H. , Kawashima, Ryo, Parrish, Karen E. , Carlson, Brett L. , Mladek, Ann C. , Decker, Paul A. , Kitange, Gaspar J. , Shen, Yuqiao , Feng, Ying , Protter, Andrew A., Elmquist, William F. , Gupta, Shiv K. , Chang, Kenneth , Bakken, Katrina K. , Schroeder, Mark A. , Kizilbash, Sani H , Chang, Kenneth Tou En , Decker, Paul A. , Sarkaria, Jann N. , Mladek, Ann C

Mayo Clinic

Molecular Cancer Therapeutics | September 25, 2017 | Volume: 16 | Issue: 12 | Pages: 2735-2746

10.1158/1535-7163.mct-17-0365 | PMID 28947502 Get It

Abstract Poly ADP-ribose polymerase (PARP) inhibitors, including talazoparib, potentiate temozolomide efficacy in multiple tumor types; however, talazoparib-mediated sensitization has not been evaluated in orthotopic glioblastoma (GBM) models. This study evaluates talazoparib ± temozolomide in clinically relevant GBM models. Talazoparib at 1–3 nmol/L sensitized T98G, U251, and GBM12 cells to temozolomide, and enhanced DNA damage signaling and G2–M arrest in vitro. In vivo cyclical therapy with talazoparib (0.15 mg/kg twice daily) combined with low-dose temozolomide (5 mg/kg daily) was well tolerated. This talazoparib/temozolomide regimen prolonged tumor stasis more than temozolomide alone in heterotopic GBM12 xenografts [median time to endpoint: 76 days versus 50 days temozolomide (P = 0.005), 11 days placebo (P < 0.001)]. However, talazoparib/temozolomide did not accentuate survival beyond that of temozolomide alone in corresponding orthotopic xenografts [median survival 37 vs. 30 days with temozolomide (P = 0.93), 14 days with placebo, P < 0.001]. Average brain and plasma talazoparib concentrations at 2 hours after a single dose (0.15 mg/kg) were 0.49 ± 0.07 ng/g and 25.5±4.1 ng/mL, respectively. The brain/plasma distribution of talazoparib in Bcrp−/− versus wild-type (WT) mice did not differ, whereas the brain/plasma ratio in Mdr1a/b−/− mice was higher than WT mice (0.23 vs. 0.02, P < 0.001). Consistent with the in vivo brain distribution, overexpression of MDR1 decreased talazoparib accumulation in MDCKII cells. These results indicate that talazoparib has significant MDR1 efflux liability that may restrict delivery across the blood–brain barrier, and this may explain the loss of talazoparib-mediated temozolomide sensitization in orthotopic versus heterotopic GBM xenografts. Mol Cancer Ther; 16(12); 2735–46. ©2017 AACR.
Implantable cardiac defibrillator infections: the emerging importance of Mycobacterium fortuitum
Orellana-Barrios, Menfil , Oyenuga, Olusegun, Nugent, Kenneth , Sotello Aviles, David A , Sotello, David

Mayo Clinic

BMJ Case Reports | September 19, 2017 | Volume: 2017 | Issue: No issue available | Pages: bcr-2017-221934

10.1136/bcr-2017-221934 | PMID 28928258 Get It

Infection is a clinically relevant complication associated with intracardiac devices. Atypical mycobacteria, particularly Mycobacterium fortuitum, have been increasingly implicated in cardiovascular implantable electronic device (CIED) infections. We present a case of M. fortuitum CIED infection in a patient with ischaemic cardiomyopathy occurring approximately 3 weeks after insertion. The recognition and adequate treatment, including device removal, tissue sampling and the determination of antimicrobial sensitivities, are essential in the proper management of these patients.
Human Papillomavirus Vaccine and Postural Orthostatic Tachycardia Syndrome: A Review of Current Literature
Butts, Breann N. , Mack, Kenneth J. , Fischer, Philip R. , Butts, Breann N.

Mayo Clinic

Journal of Child Neurology | September 8, 2017 | Volume: 32 | Issue: 11 | Pages: 956-965

10.1177/0883073817718731 | PMID 28689455 Get It

The human papillomavirus (HPV) vaccine is efficacious in preventing complications of human papillomavirus infection including cervical cancer. However, there have been case reports of adverse events occurring after vaccination, one being postural orthostatic tachycardia syndrome (POTS). This article reviews published data and other available information regarding the relationship between the human papillomavirus vaccine and POTS. Background information is provided regarding the human papillomavirus vaccine and the proposed post-vaccination adverse event POTS. Peer-reviewed literature, statements by government and medical advisory committees, and publicly available information published on this topic are examined. At this time, there is no conclusive evidence supporting a causal relationship between the human papillomavirus vaccine and POTS. Though a causal relationship has been postulated, it is of utmost importance to recognize that while temporal associations may be observed, conclusions of causality cannot be drawn from case reports and case series due to the small sample size and lack of control population.
Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers
Javed, Ammar A. , Thoburn, Christopher J. , Wong, Fay , Tie, Jeanne , Allen, Peter J., Schattner, Mark , Petersen, Gloria M. , Hong, Seung‐Mo , Falconi, Massimo , Weiss, Matthew J. , Ahuja, Nita , He, Jin , Makary, Martin A. , Molin, Marco Dal , Li, Lu , Ptak, Janine , Dobbyn, Lisa , Silliman, Natalie , Hruban, Ralph H. , Wolfgang, Christopher L. , Papadopoulos, Nickolas , Kinzler, Kenneth W. , Vogelstein, Bert , Lennon, Anne Marie , Thoburn, Christopher , Javed, Ammar A , Tie, Jeanne , Lennon, Anne Marie , Cohen, Joshua D. , Gibbs, Peter , Schmidt, Christian Max , YIP-SCHNEIDER, Michele T. , Brand, Randall E. , Singhi, Aatur Dilip , Kim, Song Cheol , Doglioni, Claudio , Maitra, Anirban , Hanash, Samir , Wang, Yuxuan , Schaefer, Joy , Popoli, Maria , Goggins, Michael , Klein, Alison P. , Tomasetti, Cristian , Massimo, Falconi

Mayo Clinic

Proceedings of the National Academy of Sciences | September 5, 2017 | Volume: 114 | Issue: 38 | Pages: 10202-10207

10.1073/pnas.1704961114 | PMID 28874546 Get It

Significance Few patients with pancreatic cancer survive longer than 5 y, in part because most patients are identified only after their disease has progressed to an advanced stage. In this study, we show how combining mutations in circulating tumor DNA (ctDNA) with protein markers can result in a screening test with improved sensitivity while retaining specificity. The combination of the ctDNA and protein markers was superior to any single marker. Moreover, the combination detected nearly two-thirds of pancreatic cancers that had no evidence of distant metastasis at the time of surgical resection. The strategy may represent an approach to detect cancers of many types at an earlier stage.
Relating gastric scintigraphy and symptoms to motility capsule transit and pressure findings in suspected gastroparesis
Hasler, William L. , May, Kevin P. , Wilson, Laura , Natta, Mark L. Van , Parkman, Henry P. , Pasricha, Pankaj J. , Koch, Kenneth L. , Abell, Thomas L. , McCallum, Richard W. , Snape, William J., Sarosiek, Irene , Farrugia, Gianrico , Calles-Escandón, Jorge, Grover, Madhusudan , Tonascia, James , Lee, L. A., Miriel, Laura , Hamilton, Frank A., Hasler, W L , Parkman, H P , Abell, T L , Nguyen, Linda Anh B. , Clarke, John O.

Mayo Clinic

Neurogastroenterology & Motility | September 5, 2017 | Volume: 30 | Issue: 2 | Pages: No page available

10.1111/nmo.13196 | PMID 28872760 Get It

Abstract Background Wireless motility capsule ( WMC ) findings are incompletely defined in suspected gastroparesis. We aimed to characterize regional WMC transit and contractility in relation to scintigraphy, etiology, and symptoms in patients undergoing gastric emptying testing. Methods A total of 209 patients with gastroparesis symptoms at NIDDK Gastroparesis Consortium centers underwent gastric scintigraphy and WMC s on separate days to measure regional transit and contractility. Validated questionnaires quantified symptoms. Key Results Solid scintigraphy and liquid scintigraphy were delayed in 68.8% and 34.8% of patients; WMC gastric emptying times ( GET ) were delayed in 40.3% and showed 52.8% agreement with scintigraphy; 15.5% and 33.5% had delayed small bowel ( SBTT ) and colon transit ( CTT ) times. Transit was delayed in ≥2 regions in 23.3%. Rapid transit was rarely observed. Diabetics had slower GET but more rapid SBTT versus idiopathics ( P ≤ .02). GET delays related to greater scintigraphic retention, slower SBTT , and fewer gastric contractions ( P ≤ .04). Overall gastroparesis symptoms and nausea/vomiting, early satiety/fullness, bloating/distention, and upper abdominal pain subscores showed no relation to WMC transit. Upper and lower abdominal pain scores ( P ≤ .03) were greater with increased colon contractions. Constipation correlated with slower CTT and higher colon contractions ( P = .03). Diarrhea scores were higher with delayed SBTT and CTT ( P ≤ .04). Conclusions & Inferences Wireless motility capsules define gastric emptying delays similar but not identical to scintigraphy that are more severe in diabetics and relate to reduced gastric contractility. Extragastric transit delays occur in >40% with suspected gastroparesis. Gastroparesis symptoms show little association with WMC profiles, although lower symptoms relate to small bowel or colon abnormalities.
Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers
Kim, Jung-Sun , Bamlet, William R. , Oberg, Ann L. , Chaffee, Kari G. , Donahue, Greg , Cao, Xing-Jun , Chari, Suresh T. , García, Benjamin A. , Petersen, Gloria M. , Zaret, Kenneth S. , Rabe, Kari G. , Kim, Jungsun , Chari, Suresh, Bamlet, William R , Cao, Xing-Jun , Chari, Suresh T

Mayo Clinic

Science Translational Medicine | August 31, 2017 | Volume: 9 | Issue: 398 | Pages: No page available

10.1126/scitranslmed.aah5583 | PMID 28701476 Get It

THBS2 and CA19-9 markers in human blood improve detection of pancreatic ductal adenocarcinoma.
Intravesical rAd–IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin–Refractory or Relapsed Non–Muscle-Invasive Bladder Cancer: A Phase II Randomized Study
Boorjian, Stephen A. , Canter, Daniel , Ogan, Kenneth , Downs, Tracy M. , Gomella, Leonard G. , Svatek, Robert S. , Bivalacqua, Trinity J. , Grubb, Robert L. , Krupski, Tracey L. , Inman, Brant A. , Milowsky, Matthew I. , Boyd, Alan , Treasure, F. Peter, Gregory, Gillian , Sawutz, David G., Parker, Nigel, Dinney, Colin P. , Canter, Daniel J, Karsh, Lawrence I, Woods, Michael E. , Yla-Herttuala, Seppo, Parker, Nigel R, Dinney, Colin P N, Inman, Brant A , Shore, Neal D. , Karsh, Lawrence Ivan , Kamat, Ashish M. , Lotan, Yair , Lerner, Seth P. , Ylä-Herttuala, Seppo

Mayo Clinic

Journal of Clinical Oncology | August 23, 2017 | Volume: 35 | Issue: 30 | Pages: 3410-3416

10.1200/jco.2017.72.3064 | PMID 28834453 Get It

Purpose Many patients with high-risk non–muscle-invasive bladder cancer (NMIBC) are either refractory to bacillus Calmette-Guerin (BCG) treatment or may experience disease relapse. We assessed the efficacy and safety of recombinant adenovirus interferon alfa with Syn3 (rAd–IFNα/Syn3), a replication-deficient recombinant adenovirus gene transfer vector, for patients with high-grade (HG) BCG-refractory or relapsed NMIBC. Methods In this open-label, multicenter (n = 13), parallel-arm, phase II study ( ClinicalTrials.gov identifier: NCT01687244), 43 patients with HG BCG-refractory or relapsed NMIBC received intravesical rAd–IFNα/Syn3 (randomly assigned 1:1 to 1 × 10 11 viral particles (vp)/mL or 3 × 10 11 vp/mL). Patients who responded at months 3, 6, and 9 were retreated at months 4, 7, and 10. The primary end point was 12-month HG recurrence-free survival (RFS). All patients who received at least one dose were included in efficacy and safety analyses. Results Forty patients received rAd–IFNα/Syn3 (1 × 10 11 vp/mL, n = 21; 3 × 10 11 vp/mL, n = 19) between November 5, 2012, and April 8, 2015. Fourteen patients (35.0%; 90% CI, 22.6% to 49.2%) remained free of HG recurrence 12 months after initial treatment. Comparable 12-month HG RFS was noted for both doses. Of these 14 patients, two experienced recurrence at 21 and 28 months, respectively, after treatment initiation, and one died as a result of an upper tract tumor at 17 months without a recurrence. rAd–IFNα/Syn3 was well tolerated; no grade four or five adverse events (AEs) occurred, and no patient discontinued treatment because of an adverse event. The most frequently reported drug-related AEs were micturition urgency (n = 16; 40%), dysuria (n = 16; 40%), fatigue (n = 13; 32.5%), pollakiuria (n = 11; 28%), and hematuria and nocturia (n = 10 each; 25%). Conclusion rAd—IFNα/Syn3 was well tolerated. It demonstrated promising efficacy for patients with HG NMIBC after BCG therapy who were unable or unwilling to undergo radical cystectomy.
Disease understanding in patients newly diagnosed with atrial fibrillation
Kaufman, Brystana G. , Kim, Sunghee , Pieper, Karen S. , Ezekowitz, Michael D. , Mahaffey, Kenneth W. , Singer, Daniel E. , Ansell, Jack , Kowey, Peter R. , Rieffel, James A, Piccini, Jonathan P. , O’Brien, Emily C. , Allen, Larry A. , Gersh, Bernard J. , Naccarelli, Gerald V. , Fonarow, Gregg C. , Chan, Paul S. , Freeman, James V. , Peterson, Eric D.

Mayo Clinic

Heart | August 8, 2017 | Volume: 104 | Issue: 6 | Pages: 494-501

10.1136/heartjnl-2017-311800 | PMID 28790169 Get It

Objective To describe self-reported disease understanding for newly diagnosed patients with atrial fibrillation (AF) and assess (1) how disease understanding changes over the first 6 months after diagnosis and (2) the relationship between patient understanding of therapies at baseline and treatment receipt at 6 months among treatment-naïve patients. Methods We analysed survey data from SATELLITE (Survey of Patient Knowledge and Personal Priorities for Treatment), a substudy of patients with new-onset AF enrolled in the national Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT) II registry across 56 US sites. Patients were surveyed at the baseline and 6-month follow-up clinic visits using Likert scales. Results Among 1004 baseline survey responses, patients’ confidence in their understanding of rhythm control, ablation, anticoagulation and cardioversion was suboptimal, with ‘high’ understanding ranging from 8.5% for left atrial appendage closure to 71.3% for rhythm therapy. Of medical history and demographic factors, education level was the strongest predictor of reporting ‘high’ disease understanding. Among the 786 patients with 6-month survey data, significant increases in the proportion reporting high understanding were observed (p<0.05) only for warfarin and direct oral anticoagulants (DOACs). With the exception of ablation, high understanding for a given therapeutic option was not associated with increased use of that therapy at 6 months. Conclusions About half of patients with new-onset AF understood the benefits of oral anticoagulant at the time of diagnosis and understanding improved over the first 6 months. However, understanding of AF treatment remains suboptimal at 6 months. Our results suggest a need for ongoing patient education. Clinical trial registration Clinicaltrials.gov. Identifier: NCT01701817.
Comprehensive biomechanical analysis of three reconstruction techniques following total sacrectomy: an in vitro human cadaveric model
Macki, Mohamed, Ramos, Rafael De la Garza , Murgatroyd, Ashley A., Mullinix, Kenneth P., Cunningham, Bryan W. , McCutcheon, Brandon A., Bydon, Mohamad , Gokaslan, Ziya L. , Sun, Xiaolei , De la Garza Ramos, Rafael

Mayo Clinic

Journal of Neurosurgery: Spine | August 4, 2017 | Volume: 27 | Issue: 5 | Pages: 570-577

10.3171/2017.2.spine161128 | PMID 28777063 Get It

OBJECTIVEAggressive sacral tumors often require en bloc resection and lumbopelvic reconstruction. Instrumentation failure and pseudarthrosis remain a clinical concern to be addressed. The objective in this study was to compare the biomechanical stability of 3 distinct techniques for sacral reconstruction in vitro.METHODSIn a human cadaveric model study, 8 intact human lumbopelvic specimens (L2–pelvis) were tested for flexion-extension range of motion (ROM), lateral bending, and axial rotation with a custom-designed 6-df spine simulator as well as axial compression stiffness with the MTS 858 Bionix Test System. Biomechanical testing followed this sequence: 1) intact spine; 2) sacrectomy (no testing); 3) Model 1 (L3–5 transpedicular instrumentation plus spinal rods anchored to iliac screws); 4) Model 2 (addition of transiliac rod); and 5) Model 3 (removal of transiliac rod; addition of 2 spinal rods and 2 S-2 screws). Range of motion was measured at L4–5, L5–S1/cross-link, L5–right ilium, and L5–left ilium.RESULTSFlexion-extension ROM of the intact specimen at L4–5 (6.34° ± 2.57°) was significantly greater than in Model 1 (1.54° ± 0.94°), Model 2 (1.51° ± 1.01°), and Model 3 (0.72° ± 0.62°) (p < 0.001). Flexion-extension at both the L5–right ilium (2.95° ± 1.27°) and the L5–left ilium (2.87° ± 1.40°) for Model 3 was significantly less than the other 3 cohorts at the same level (p = 0.005 and p = 0.012, respectively). Compared with the intact condition, all 3 reconstruction groups statistically significantly decreased lateral bending ROM at all measured points. Axial rotation ROM at L4–5 for Model 1 (2.01° ± 1.39°), Model 2 (2.00° ± 1.52°), and Model 3 (1.15° ± 0.80°) was significantly lower than the intact condition (5.02° ± 2.90°) (p < 0.001). Moreover, axial rotation for the intact condition and Model 3 at L5–right ilium (2.64° ± 1.36° and 2.93° ± 1.68°, respectively) and L5–left ilium (2.58° ± 1.43° and 2.93° ± 1.71°, respectively) was significantly lower than for Model 1 and Model 2 at L5–right ilium (5.14° ± 2.48° and 4.95° ± 2.45°, respectively) (p = 0.036) and L5–left ilium (5.19° ± 2.34° and 4.99° ± 2.31°) (p = 0.022). Last, results of the axial compression testing at all measured points were not statistically different among reconstructions.CONCLUSIONSThe addition of a transverse bar in Model 2 offered no biomechanical advantage. Although the implementation of 4 iliac screws and 4 rods conferred a definitive kinematic advantage in Model 3, that model was associated with significantly restricted lumbopelvic ROM.
Criteria for Risk Stratification of Vulvar and Vaginal Smooth Muscle Tumors
Sayeed, Sadia , Xing, Deyin , Weisman, Paul , Buehler, Darya, Warmke, Laura M. , Uram–Tuculescu, Cora, Howitt, Brooke E. , Cortese, Cherise , Schoolmeester, J. Kenneth , Jenkins, Sarah , Bakkum‐Gamez, Jamie N. , Park, Kay J.

Mayo Clinic

American Journal of Surgical Pathology | August 4, 2017 | Volume: 42 | Issue: 1 | Pages: 84-94

10.1097/pas.0000000000000920 | PMID 28786880 Get It

Accurate risk stratification of smooth muscle tumors (SMTs) is essential for appropriate patient management. Yet, the rarity of SMTs of the vagina and vulva makes development of a prognostically meaningful classification system challenging. While 2 classification methods for vulvar SMTs and 1 for vaginal SMTs have been proposed, it is our experience that many pathologists tend to apply criteria for uterine SMTs when evaluating vulvovaginal tumors. We retrospectively reviewed a large cohort of vulvovaginal SMTs with clinical follow-up and evaluated which method most accurately classified tumors according to patient outcome. A total of 71 tumors, 53 vaginal (75%) and 18 vulvar (25%), from 71 patients were identified. All tumors were centrally examined for degree of cytologic atypia, morphology (spindled, epithelioid, myxoid), mitotic index per 10 high power fields, atypical mitotic figures, tumor cell necrosis, ischemic necrosis, tumor interface (circumscribed or infiltrative) and margin status. Clinical features were recorded for each patient. Follow-up was available for 63 patients (89%), and ranged from 1 to 234 months (median: 64 mo). While site-specific and uterine criteria showed equally excellent sensitivity in classifying smooth muscle neoplasms as leiomyosarcoma according to patient outcome, uterine criteria showed improved specificity relatively to site-specific methods in classifying tumors as nonsarcoma according to patient outcome. We recommend that uterine SMT criteria and nomenclature be adopted for evaluation and classification of vulvovaginal SMTs.